Litcius/Paper detail

Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial

Joseph M. Letourneau, Flor Juarez‐Hernandez, Kaitlyn Wald, Salustiano Ribeiro, Ange Wang, Charles E. McCulloch, Evelyn Mok-Lin, Marek Doležal, A. Jo Chien, Marcelle I. Cedars, Mitchell P. Rosen

2021Journal of Assisted Reproduction and Genetics22 citationsDOIOpen Access PDF

Topics & Concepts

LetrozoleTamoxifenFertility preservationBreast cancerAntiestrogenMedicineGynecologyOncologyEstrogenConcomitantRandomized controlled trialFertilitySelective estrogen receptor modulatorOvarian reserveReproductive medicineInternal medicineCancerInfertilityBiologyPregnancyEnvironmental healthGeneticsPopulationReproductive Biology and FertilityBreast Cancer Treatment StudiesCancer Risks and Factors
Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial | Litcius